

# The Effect of median Nerve Stimulation On cardiac electRophysiology (TENSOR)

Published: 18-02-2025

Last updated: 07-06-2025

The primary objective of this pilot study is to examine the impact of MNS on cardiac electrophysiology measured at a high-resolution scale during SR.

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruiting
<b>Health condition type</b>	Cardiac arrhythmias
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON57314

### Source

ToetsingOnline

### Brief title

TENSOR

## Condition

- Cardiac arrhythmias

### Synonym

Atrial fibrillation

### Research involving

Human

## Sponsors and support

**Primary sponsor:** Erasmus MC, Universitair Medisch Centrum Rotterdam

**Source(s) of monetary or material Support:** Ministerie van OC&W

## Intervention

**Keyword:** Atrial fibrillation, Effect on cardiac electrophysiology, Median nerve stimulation

## Outcome measures

### Primary outcome

The impact of MNS on cardiac electrophysiological properties, such as the unipolar potential slope and conduction disorders, measured during SR.

### Secondary outcome

None

## Study description

### Background summary

Mortality, morbidity and health care costs due to atrial fibrillation (AF) are worldwide growing problems and therapeutic interventions for AF are often not effective. For many years, it has been suggested that the autonomic nervous system (ANS) plays an important role in AF pathogenesis. The ANS may either induce remodelling in the atria or undergo remodelling itself, thereby serving as a substrate for AF. Several critical points within the cardiac neural axis serve as targets for therapeutic intervention. Studies have demonstrated the effectiveness of neuromodulation therapy for AF, including low-level vagus nerve stimulation (LLVNS), stellate ganglion block, or ganglionated plexi ablation, in reducing AF inducibility, incidence, and burden. Recently, median nerve stimulation (MNS) has also been found to have antiarrhythmic effects. There is evidence that MNS prevents atrial effective refractory period (AERP) shortening and increased AF inducibility during rapid atrial pacing. A wearable device has been designed for MNS, and preliminary data within the AF population indicate the potential of this device in treating AF.

Previous mapping study indicates that LLVNS affects electrophysiological properties during sinus rhythm (SR). However, the underlying electrophysiological mechanism is unknown.

### Study objective

The primary objective of this pilot study is to examine the impact of MNS on cardiac electrophysiology measured at a high-resolution scale during SR.

### Study design

This pilot study is designed as an interventional study.

## Intervention

High-resolution cardiac mapping during SR

## Study burden and risks

Neither the patient, nor the investigators are in any way compensated for their participation with regards to this study. The risks associated with participation are known to be negligible, since epicardial mapping using the non-investigational product (see Medical Device Dossier) in over 1500 patients in previous METC-approved studies (MEC 2010-054, MEC 2014-393, MEC 2015-373, MEC 2019-543, MEC 2020-0124) did not cause any complications. The duration of the surgical procedure is minimally prolonged by the epicardial mapping procedure with an estimate of 8-10 minutes.

Studies in different medical fields have shown that MNS is a safe treatment modality. Patients may benefit from this study as MNS has been shown to prevent AERP shortening and increased AF inducibility during rapid atrial pacing. Moreover, this novel therapy may serve as a treatment of AF in non-surgical patients. At the same time, the device's wearable nature and monitoring capabilities have emerged as key advantages for patients, facilitating treatment and enabling adjustments to care plans.

## Contacts

### Public

Erasmus MC, Universitair Medisch Centrum Rotterdam

's Gravendijkwal 230  
Rotterdam 3015 CE  
NL

### Scientific

Erasmus MC, Universitair Medisch Centrum Rotterdam

's Gravendijkwal 230  
Rotterdam 3015 CE  
NL

## Trial sites

## Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

Age equal or older than 18 years

Ischemic heart disease

Scheduled for elective cardiothoracic surgery

### Exclusion criteria

Hemodynamic instability

Usage of inotropic agents

Emergency cardiac surgery

Prior left-sided radiation of the chest for malignancies

## Study design

### Design

**Study type:** Interventional

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Treatment

### Recruitment

NL

Recruitment status: Recruiting

Start date (anticipated): 25-02-2025

Enrollment: 53

Type: Actual

## Medical products/devices used

Generic name: CardiaCare RR2 median nerve stimulator

Registration: No

## Ethics review

Approved WMO

Date: 18-02-2025

Application type: First submission

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

**Register**

CCMO

**ID**

NL87294.078.24